A detailed history of Srs Capital Advisors, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 348 shares of VRTX stock, worth $163,476. This represents 0.02% of its overall portfolio holdings.

Number of Shares
348
Previous 56 521.43%
Holding current value
$163,476
Previous $23,000 608.7%
% of portfolio
0.02%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

BUY
$392.81 - $485.53 $114,700 - $141,774
292 Added 521.43%
348 $163,000
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $1,572 - $1,759
5 Added 9.8%
56 $19,000
Q1 2023

May 16, 2023

BUY
$283.23 - $323.1 $3,681 - $4,200
13 Added 34.21%
51 $16,000
Q4 2022

Feb 24, 2023

BUY
$285.76 - $321.48 $857 - $964
3 Added 8.57%
38 $10,000
Q3 2022

Nov 03, 2022

SELL
$273.83 - $305.53 $2,738 - $3,055
-10 Reduced 22.22%
35 $10,000
Q2 2022

Aug 22, 2022

BUY
$234.96 - $292.55 $5,404 - $6,728
23 Added 104.55%
45 $13,000
Q1 2022

May 12, 2022

SELL
$221.42 - $260.97 $6,199 - $7,307
-28 Reduced 56.0%
22 $6,000
Q4 2021

Feb 08, 2022

SELL
$177.01 - $223.45 $2,655 - $3,351
-15 Reduced 23.08%
50 $11,000
Q3 2021

Nov 05, 2021

BUY
$181.39 - $202.99 $906 - $1,014
5 Added 8.33%
65 $12,000
Q2 2021

Aug 02, 2021

SELL
$187.49 - $221.1 $749 - $884
-4 Reduced 6.25%
60 $12,000
Q4 2020

Feb 03, 2021

BUY
$207.01 - $276.09 $828 - $1,104
4 Added 6.67%
64 $15,000
Q4 2019

Feb 07, 2020

BUY
$166.71 - $223.91 $3,667 - $4,926
22 Added 57.89%
60 $13,000
Q3 2018

Nov 06, 2018

SELL
$167.73 - $192.74 $3,690 - $4,240
-22 Reduced 36.67%
38 $7,000
Q2 2018

Aug 21, 2018

SELL
$145.72 - $169.96 $728 - $849
-5 Reduced 7.69%
60 $10,000
Q1 2018

May 14, 2018

BUY
$151.6 - $177.13 $4,093 - $4,782
27 Added 71.05%
65 $10,000
Q4 2017

Feb 15, 2018

SELL
$137.28 - $155.55 $686 - $777
-5 Reduced 11.63%
38 $5,000
Q3 2017

Nov 15, 2017

BUY
$148.13 - $162.24 $6,369 - $6,976
43
43 $6,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $121B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Srs Capital Advisors, Inc. Portfolio

Follow Srs Capital Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Srs Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Srs Capital Advisors, Inc. with notifications on news.